Arylamine N-acetyltransferase in erythrocytes of cystic fibrosis patients

Pharmacology and Toxicology

Volumn 78, Issue 4, 1996, Pages 235-240

  Risch, Angela ^a   Smelt, Valerie ^a   Lane, Donald ^b   Stanley, Lesley ^a   Van Der Slot, Wilma ^a   Ward, Alison ^a   Sim, Edith ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ISOENZYME; SULFAMETHOXAZOLE;

ADULT; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; ENZYME ACTIVITY; ERYTHROCYTE; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0029993383     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1996.tb00211.x     Document Type: Article

References (43)

1. Alton, E. & D. Geddes: Gene therapy for cystic fibrosis: a clinical perspective. Nature Genetics 1994, 8, 8-9.
2. Bell, D. A., J. A. Taylor, M. A. Butler, E. A. Stephens, J. Wiest, L. H. Brubaker, F. F. Kadlubar & G. W. Lucier: Genotype/phenotype discordance for human arylamine N-acetyltransferase2 reveals a new slow acetylator allele common in African-Americans. Carcinogenesis 1993, 14, 1689-1692.
3. Bell, D. A., E. A. Stephens, T. Castriano, D. M. Umbach, M. Watson, M. Deakin, J. Elder, C. Hendrichse, H. Duncan & R. C. Strange: Polyadenylation polymorphism in the acetyltransferase 1 Gene (NAT1) increases risk of colorectal cancer. Cancer Res. 1995, 55, 3537-3542.
4. Blum, M., D. M. Grant, W. McBride, M. Heim & U. A. Meyer: Human arylamine N-acetyltransferase genes: isolation, chromosomal localisation and functional expression. DNA Cell Biol. 1990, 9, 192-203.
5. Blum, M., A. Demierre, D. M. Grant, M. Heim & U. A. Meyer: Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc. Natl. Acad. Sci. USA. 1991, 88, 5237-5241.
6. Coroneos, E. & E. Sim: N-acetyltransferase in human urothelium and bladder cell lines. Biochem. Soc. Trans. 1991, 19, 129s.
7. Coroneos, E. & E. Sim: Arylamine N-acetyltransferase activity in human cultured cells. Biochem. J. 1993, 294, 481-486.
8. Crawford, I., P. C. Maloney, K. L. Zeitlin, W. B. Guggino, S. C. Hyde, H. Turley, K. C. Gatter & A. Harris, Higgins cystic fibrosis. Immunocytochemical localisation of the cystic fibrosis gene product CFTR. Proc. Natl. Acad. Sci. USA 1991, 88, 9262-9266.
9. Cribb, A.E., R. Isbruker, T. Levatte, B. Tsui, C. T. Gillespie & K. W. Renton: Acetylator phenotyping: the urinary caffeine metabolite ratio correlates in slow acetylators correlates with a marker of sytemic arylamine N-acetyltransferase 1 activity. Pharmacogenetics 1994, 4, 166-170.
10. Cribb, A. E., D. M. Grant, M. Miller & S. P. Spielberg: Expression of monomorphic (arylamine N-acetyltransferase 1) arylamine N-acetyltransferase in mononuclear leukocytes. J. Pharmacol. Exp. Therap. 1991, 259, 1241-1246.
11. Cribb, A.E., B. Tsui, R. Isbrucker, R. T. Michael, C. T. Gillespie, J. Brown-Bonomo, P. Barrett, T. Levatte & K. W. Renton: Assessment of arylamine N-acetyltransferase in cystic fibrosis patients. Brit. J. Clin. Pharm. 1995, 39, 85-89.
12. Cribb, A. E., H. Nakamura, D. M. Grant, M. A. Mille & S. P. Spielberg: Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulphamethoxazole metabolism. Biochem. Pharmacol. 1993, 45, 1277-1282.
13. Dacie, J. V.: Practical haematology. J&E Churchill, London, 1958, p. 46.
14. Deguchi, T., M. Mashimo & T. Suzuki: Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J. Biol. Chem. 1990, 265, 12757-12760.
15. Dupret, J.-M., G. H. Goodfellow, S. A. Janezic & D. M. Grant: Structure-function studies of human arylamine N-acetyltransferases arylamine N-acetyltransferase-1 and arylamine N-acetyltransferase-2. J. Biol. Chem. 1994, 269, 26830-26835.
16. Frinkelstein, E. & K. Hall: Aminoglycoside clearance in cystic fibrosis. J. Paediat. 1979, 94, 163-164.
17. Hamelin, B. A., K. Xu, F. Valle, L. Manseau, M. Richter & M. LeBel: Caffeine metabolism in cystic fibrosis: enhanced xanthine oxidase activity. Clin. Pharmacol. Therap. 1994, 56, 521-529.
18. Hein, D. W., T. D. Rustan, R. J. Ferguson, M. A. Doll & K. Gray: Metabolic activation of aromatic and heterocyclic N-hydroxylamines by wild-type and mutant recombinant human arylamine N-acetyltransferase 1 and arylamine N-acetyltransferase 2 acetyltransferases. Arch. Tox. 1994, 68, 129-313.
19. Hickman, D. & K. Sim: N-acetyltransferase polymorphism-comparison of phenotype and genotype in humans. Biochem. Pharmacol. 1991, 42, 1007-1014.
20. Hickman, D., A. Risch, J. Camilleri & E. Sim: Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants. Pharmacogenetics 1992, 2, 217-226.
21. Hickman, D., A. Risch, V. Buckle, N. K. Spurr & E. Sim: Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem. J. 1994, 297, 441-445.
22. Hull, J., S. Shackleton & A. Harris: Abnormal mRNSA splicing resulting from 3 different mutations in the CFTR gene. Human Mol. Genet. 1993, 2, 689-692.
23. Hutabarat, R. M., A. L. Smith & J. D. Unadkat: Disposition of drugs in cystic fibrosis. VII Acetylation of sulphamethoxazole in blood cells: In vitro-in vivo correlation and characterisation of its kinetics of acetylation in lymphocytes. Clin. Pharm. Therapeut. 1994, 55, 427-433.
24. Hutabarat, R. M., J. D. Unadkat, C. Sahajwalla, S. McNamara, B. Ransey & A. L. Smith: Disposition of drugs in cystic fibrosis 1 Sulphamethoxazole and trimethoprim. Clin. Pharm. Therapeut. 1991, 49, 402-409.
25. Jenne, J. W.: Partial purification and properties of the isoniazid transacetylase from human liver and its relationship to the acetylation of p-aminosalicylic acid. J. Clin. Invest. 1965, 44, 1992-2002.
26. Kelly, S. K. & E. Sim: Expression of N-acetyltransferase in a human monocytic cell line. U937. Human Exp. Toxicol. 1991, 10, 33-38.
27. Koren, G., Z. Weizman, G. Forstner, S. M. MacLoed & P. R. Durie: Altered PABA pharmacokinetics in cystic fibrosis: implications for bentromide test. Digestive Diseases and Sci. 1985, 30, 928-932.
28. Lindsay, R. M. & J. D. Baty: Inter-individual variation of human blood N-acetyltransferase activity in vitro. Biochem. Pharmacol. 1988, 37, 3915-3921.
29. McQueen, C. A. & W. W. Weber. Characterization of human lymphocyte N-acetyltransferase and its relationship to isoniazid acetylator polymorphism. Biochem. Genetics 1980, 18, 899-904.
30. Mearns, M. B.: In: Cystic fibrosis: The first 50 years. Eds.: J. A. Dodge, D. H. Brock, J. H. Widdicombe, John Wiley & Sons, New York, 1993, pp. 217-250.
31. Ohsako, S. & T. Deguchi: Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J. Cell Biol. 1990, 265, 4630-4634.
32. Palamanda, J., D. Hickman, A. Ward, E. Sim & J. D. Unadkat: Dapsone acelylation by human liver N-acetyltransferase and interactin with anti-opportunistic infection drugs. Drug. Metab. Disp. 1995, 23, 473-177.
33. Prandota, J.: Clinical pharmacology ol antibiotics and other drugs in cystic fibrosis. Drugs 1988, 35, 542-578.
34. Reed, M. D., R. C. Stern, J. S. Bertino, C. M. Myers & T. S. Yamashita: Dosing implications of rapid elimiaryalamine N-acetyltransferaseion of trimethoprim-sulphamethoxazole in patients with cystic fibrosis. J. Paediatrics 1984, 104, 303-307.
35. Riordan, J. R., J. M. Rommens, B. S. Kerem, N. Alon, R. Rozmahel, Z. Grzelczak, J. Zielinski, S. Lok, N. Plavsic, J. L. Chou, M. L., Drumm, M. C. Iannuzzi, F. S. Collins & L. C. Tsui: Identification of the cystic fibrosis gene, cloning and characterisation of cDNA. Science 1989, 245, 1066-1073.
36. Risch, A., D. M. A. Wallace, S. Bathers & E. Sim: Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Human Mol. Genet. 1995, 4, 231-236.
37. Spino, M.: Pharmacokinetics of drugs in cystic fibrosis. Clin. Rev. Allergy 1991, 9, 169-210.
38. Vatsis, K. P. & W. W. Weber: Structral heterogeneity of Caucasian N-acetyltransferase at the arylamine N-acetyltransferase 1 gene locus. Arch. Biochem. Biophys. 1993, 44, 71-76.
39. Vatsis, K. P., W. W. Weber, D. A. Bell, D.-M. Dupret, D. A. Price-Evans, D. M. Grant, D. W. Hein, H. J. Lin, U. A. Meyer, M. V. Relling, E. Sim, T. Suzuki & Y. Yamazoe: Nomencature for N-acetyltransferases. Pharmacogenetics 1995, 5, 1-27.
40. Vree, T. B. & Y. A. Hekster: Clinical pharmycokinetics of sulphonamides and their metabolites. Antibiotics and Chemotherapy 1987, 37, 1-214.
41. Ward, A., D. Hickman, J. Gordon & E. Sim: Arylamine N-acetyltransferase in human red blood cells. Biochem. Pharmacol. 1992, 44, 1099-1104.
42. Ward, A., M. J. Summers & E. Sim: Purification of recombinant human N-acetyltransferase type 1 (NAT1) expressed in E. coli and characterisation of its potential role in folate metabolism. Biochem. Pharm. 1995, 49, 1759-1767.
43. Weber, W. W. & K. P. Vatsis: Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (arylamine N-acetyltransferase 1) of peripheral blood. Pharmacogenetics 1993, 3, 209-212.